• / Free eNewsletters & Magazine
  • / My Account
Home>Funds>Rydex Inverse 2x S&P MidCap 400

Rydex Inverse 2x S&P MidCap 400

  1. All
  2. Morningstar Articles
  3. 3rd Party
  1. New Data at EAN Show Genentech’s Ocrevus (Ocrelizumab) Significantly Reduced Multiple Measures of Disease Progression in Relapsing and Primary Progressive Multiple Sclerosis

    New Data at EAN Show Genentech’s Ocrevus (Ocrelizumab) Significantly Reduced Multiple Measures of Disease Progression in Relapsing and Primary Progressive Multiple Sclerosis

  2. Dubai Airports Selects Quintiq for Automated Planning Solution to Deliver World-Class Passenger Experience

    Dubai Airports Selects Quintiq for Automated Planning Solution to Deliver World-Class Passenger Experience

12

©2017 Morningstar Advisor. All right reserved.